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Adeno-associated virus (AAV) type 2 vectors transfer stable, long-term gene expression to diverse cell types
in vivo. Many gene therapy applications require the control of long-term transgene expression, and AAV
vectors, similar to other gene transfer systems, are being evaluated for delivery of regulated gene expression
cassettes. Previously, we (R. P. Haberman, T. J. McCown, and R. J. Samulski, Gene Ther. 5:1604–1611, 1998)
demonstrated the use of the tetracycline-responsive system for long-term regulated expression in rat brains. In
that study, we also observed residual expression in the “off” state both in vitro and in vivo, suggesting that the
human cytomegalovirus (CMV) major immediate-early minimal promoter or other cis-acting elements (AAV
terminal repeats [TR]) were contributing to this activity. In the present study, we identify that the AAV TR,
minus the tetracycline-responsive minimal CMV promoter, will initiate mRNA expression from vector tem-
plates. Using deletion analysis and specific PCR-derived TR reporter gene templates, we mapped this activity
to a 37-nucleotide stretch in the A/D elements of the TR. Although the mRNA derived from the TR is generated
from a non-TATA box element, the use of mutant templates failed to identify function of canonical initiator
sequences as previously described. Finally, we demonstrated the presence of green fluorescent protein expres-
sion both in vitro and in vivo in brain by using recombinant virus carrying only the TR element. Since the AAV
terminal repeat is a necessary component of all recombinant AAV vectors, this TR transcriptional activity may
interfere with all regulated expression cassettes and may be a problem in the development of novel TR split
gene vectors currently being considered for genes too large to be packaged.
Recombinant adeno-associated virus (AAV) vectors have
been studied in both large- and small-animal models and dem-
onstrate safe and effective gene transfer (22). Importantly,
AAV vectors transduce tissues for long periods, lasting over
1.5 years in the muscle and central nervous system of rodents
(27, 37). Such long-term expression suggests the possibility of
permanent gene transfer in human gene therapy. While this is
essential for the correction of genetic diseases, it raises the new
concern of properly regulating the therapeutic gene product.
Appropriate implementation of long-term gene expression
requires the ability to control the expression of virus-delivered
transgenes using either endogenous cell-type-specific promot-
ers or exogenous regulation systems. One exogenous system,
the tetracycline-regulated system, has been studied extensively
in vitro and in vivo and has been shown to give 100- to 1,000-
fold levels of regulation between the off and on states (11, 15).
By incorporating this system in an AAV vector, we demon-
strated control of reporter gene expression in the brain (13),
with a range of regulation of 28-fold in vitro and 10-fold in
vivo. Two other groups have generated tetracycline-regulated
AAV vectors that demonstrated control of the secreted eryth-
ropoietin protein after vector injection into rodent muscle,
with similar success (1, 18). While the ability to obtain regu-
lated gene expression in these studies was significant, the re-
sults were vastly different from those published using transfec-
tions in vitro or analysis of tetracycline regulation in transgenic
animals (100- to 1,000-fold). It is clear that many human gene
therapy and experimental situations will require tighter con-
trol. Our data suggest that the decreased regulation is most
likely to be due to a high background level of activity in the
“off” state. Since AAV vectors are derived from minimal cis-
acting sequences (145-bp terminal repeats), only a limited
number of components of the vector could be responsible for
this activity. This includes a portion of the tetracycline-regu-
lated promoter, the cytomegalovirus (CMV) minimal pro-
moter, and/or the AAV terminal repeats (TR). Background
expression from the minimal promoter can be significant, and
new versions of the tetracycline-regulated system are showing
promise in resolving this concern (10). However, several lines
of evidence suggest that the AAV TR may also be a source of
transcriptional elements (8, 9) that could adversely influence
regulation from the tetracycline-regulated AAV vector.
Since the AAV TRs contain all the cis-acting sequences
necessary for replication and packaging of recombinant DNA
as well as for mediating the integration of the viral DNA into
the host genome, they cannot be deleted. These sequences
have at least two different transcriptional activities in tissue
culture (8, 9). Flotte et al. (9) removed the first 83 or 140
nucleotides (nt) of the AAV TR located adjacent to a TATA
box-containing promoter and reduced expression by about
50% after plasmid transfections into an epithelial cell line. This
suggested that an enhancer activity was located somewhere in
the first 83 nt of the AAV TR. In a second study (8), they
demonstrated that the AAV TR was able to initiate gene
expression in a promoterless construct after plasmid transfec-
tion or after AAV vector infection in vitro. Thus, the TR
appears to have both promoter and enhancer activities in tissue
culture. While these studies identified enhancer and transcrip-
tional activities, further identification of the critical sequences
responsible for these observations have not been forthcoming,
probably due to the difficulty of characterizing the AAV TR.
The TR contains significant secondary structure (see Fig.
2A), which may also be responsible for the reported transcrip-
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tional activity. Due to palindromic sequences within the TR, it
is the only double-stranded portion of an otherwise single-
stranded AAV genome when packaged (7). This sequence,
which has a G1C content of over 80%, folds back on itself to
form a T-shaped structure composed of two small palin-
dromes, B and C, contained within a larger palindrome, A (see
Fig. 2A). An additional sequence, the D element, is also part of
the TR but is single stranded in the virion. The D element
contains the packaging signal (X. Xiao and R. J. Samulski,
unpublished data), and the A stem contains sequences for an
AAV Rep protein binding element (RBE), while the junction
between these two elements defines the terminal resolution
site (trs) required for viral DNA replication (2, 14, 21, 28). In
addition to the general secondary structure which may attract
transcriptional proteins (30, 34) and as initially proposed by
Flotte et al. (8), we identified two sequences in the A (nt 88 to
95) and D (nt 126 to 133) regions which have significant ho-
mology (5 of 7 bases for each) to an initiator sequence (see Fig.
2A). Initiator sequences are characterized as minimal se-
quences that are sufficient to mediate transcript initiation in
the absence of a TATA box (25, 26). Flotte et al. (8) suggested
that a putative initiator sequence may generate the promoter
activity seen in their studies with AAV. It is possible that these
sequences in the TR are sufficient to produce transcriptional
activation of a downstream gene in vitro and in vivo. To better
characterize these observations, we initiated studies aimed at
defining the role of the TR on the tetracycline-responsive vec-
tors we used in vivo.
TR-initiated expression. To better define the reason for
inefficient regulation of our tetracycline-responsive vector, a
series of promoterless plasmids were derived from TR/CMV/
GFP by restriction enzyme digestion (Fig. 1A). TRGFP-p is
identical to TR/CMV/GFP except that it is missing the CMV
promoter that is typically used to express the reporter gene,
green fluorescent protein (GFP). Superfect transfection (1 mg
of plasmid to 4 ml of Superfect reagent [Qiagen]) of TRGFP-p
into approximately 2 3 105 HEK 293 cells (data not shown) or
1 3 105 HtTA-1 cells (HeLa cells stably transfected with the
tetracycline transactivator [a gift from H. Bujard]) expressed
GFP at a low level (Fig. 1B). In HtTA-1 cells, TRGFP-p
produced detectable expression in 5 to 10% of the cells that
showed expression with TR/CMV/GFP and at a lower intensity
per cell. To ensure that this activity was not due to other
elements (e.g., the simian virus 40 [SV40] intron sequence or
plasmid readthrough by the neomycin gene promoter), TR-
pint and TR-pneo were constructed to remove these se-
quences, respectively. Transfection of each construct produced
gene expression at a level equal to or slightly greater than that
for TRGFP-p. Thus, the AAV TR in plasmid form (Fig. 2)
appears sufficient to produce low-level transcriptional activity
in tissue culture. These observations corroborated the pub-
lished results of Flotte et al. (8) using chloramphenicol acetyl-
transferase reporter gene in 293 cells.
Mapping TR promoter activity. Localization of the pro-
moter activity within the TR was investigated initially by
primer extension analysis of the mRNA start site. Our tech-
nique produced clear identification of a CMV promoter start
site but inconclusive results with the TR-generated transcripts,
presumably due to low levels of mRNA. Therefore, reverse
transcription-PCR (RT-PCR) analysis of mRNA from plasmid
substrates transfected into 293 cells was initiated to determine
an approximate start site. Products of mRNA amplification
were distinguished from any input DNA amplification by use
of an intron-containing construct. The DNA PCR products
also served as an internal control for the reaction (since they
were 100 bp larger than the spliced mRNA product). A series
of primers (Fig. 2) were used to amplify products of spliced
mRNA transcripts and 100-bp-larger products from unspliced
RNA or residual DNA (TR-pneo). Primers located 59 of the
initiation site would produce products only of unspliced length,
indicating amplification of residual DNA and not processed
mRNA. mRNA was extracted using Trizol reagent (Gibco
BRL) from 10-cm plates of TR-pneo-transfected 293 cells and
Dynal poly-T magnetic beads (as specified by the manufactur-
er). The mRNA was then subjected to RT with poly(T) primer
and avian myeloblastosis virus reverse transcriptase for 90 min
at 42°C. The RT products were PCR amplified with a series of
59 TR primers and one of two 39 primers located in the GFP
gene, under conditions optimized to detect low transcript num-
bers (1 U of Perkin-Elmer Taq polymerase, 0.2 mM each
primer, and 0.25 mM each deoxynucleoside triphosphate per
50-ml reaction mixture with 40 cycles of amplification). Gel
electrophoresis analysis of the PCR products revealed both
spliced and unspliced products from primers 2 through 6 (Fig.
2B, lanes 1, 4, and 7; Table 1), while mRNA preparations from
mock-transfected cells, spiked with DNA, yielded only un-
spliced sized products for these primers. Although the TR has
many repetitive sequences, no internal TR amplification (in-
dicated by smaller bands) was seen with these primers. Primer
7, located in the B/C region of the terminal repeat, was unable
to amplify any products of the spliced or unspliced size, even
with the use of a series of annealing temperatures and a GC-
rich sequence optimization reagent (GC melt; Clontech). This
primer is located in a GC-rich region in the middle of the
secondary structure of the terminal repeat (Fig. 2A, virus
form). Previous studies have determined that this secondary
structure interferes with PCR amplification (23, 38) and is
probably blocking amplification from primer 7. Likewise, prim-
ers located beyond the terminal repeat in the plasmid were
unable to consistently amplify products of either spliced or
unspliced size, confirming previous observations (28, 38) and
making the additional localization of transcript initiation be-
yond this secondary structure intractable. To ensure that the
spliced products detected with the initial primers were ampli-
fied from RNA, mRNA preparations were treated with 30 U of
S1 nuclease or 0.3 M NaOH for 1 h at 37°C in the presence of
glycogen and then ethanol precipitated before being subjected
to the RT step. Since S1 nuclease digestion and NaOH diges-
tion preferentially degrade single-stranded nucleic acids and
RNA, respectively, only products derived from DNA (un-
spliced size) were detected after these treatments (Fig. 2B,
lanes 2 and 3; Table 1). This approach confirmed that mRNA
transcripts originated as far back as the 59 end of the A element
(primer 6). However, because of our inability to amplify any
product upstream of primer 6, additional determinations of
any other 59 initiation sequences were not possible using this
method.
To further evaluate the TR promoter activity and the min-
imal sequences necessary for mRNA expression, PCR ampli-
fication was used to generate minimal TR/GFP cassettes,
which were purified, transfected into HtTA-1 or 293 cells, and
assayed for GFP activity. A number of the primers used to map
mRNA initiation from plasmid vector templates, along with
several additional 59 primers paired with a 39 primer located
after the poly(A) signal of the GFP gene, were used to gener-
ate these miniexpression cassettes (Fig. 3A). PCR products
were amplified from plasmid templates (TR-pneo or TR-pint)
under conditions similar to those for RT product amplification.
These products were amplified a second time to obtain enough
material for transfection into duplicate wells of a 12-well plate.
After PCR, the products were digested with DpnI, which di-
gests input plasmid DNA, for 2 h and purified on Sephadex
VOL. 74, 2000 NOTES 8733
G-25 spin columns to remove residual deoxynucleoside tri-
phosphates and primers. Products were quantified by optical
densitometry, and approximately 1.5 pmol of each product was
transfected into 293 cells or HtTA-1 cells using superfect (in
quantification experiments, equivalent amounts [in picomoles]
of each product were used). Two measurements were used to
determine relative expression: the number of GFP-positive
cells and relative whole-field fluorescence (Fig. 3A). Templates
containing only the intron (amplified using primer 2) and no
TR sequences produced a few visible cells (the number of
GFP-positive cells was 18.9% 6 5.9% of the number obtained
with control primer 5) after transfection (Fig. 3). This expres-
sion could be due to nonspecific or random initiation within
the SV40 intron. However, the levels significantly increased
(the number of GFP-positive cells was 91.8% 6 9.1% of the
number with control primer 5) after transfection of a PCR
template that included sequences of the TR, specifically the
A/D junction (primer 4). Since intron-minus templates gener-
ated from primer 4 also gave positive expression (Fig. 3B), we
concluded that the intron was not required for this increase.
PCR templates carrying a small portion of the D element
(primer 3) produced slightly lower expression than that ob-
tained with primer 2 (intron primer). This observation was very
reproducible, indicating the ability of the intron sequences to
initiate nonspecifically or the potential interference from the
cellular protein(s) previously shown to bind the AAV D ele-
FIG. 1. (A) Plasmids used for transfection. All promoterless plasmids are derived from TR-CMV-GFP by restriction digest deletion of the regions indicated.
TR-CMV-GFP was made from pTRUF 2 (39), a kind gift from N. Muzyczka, by removing the GFP gene and replacing it with the EGFP gene (Clonetech) using
convenient restriction enzymes. pCMV, cytomegalovirus immediate-early promoter; int, SV40 intron; pro, TK promoter plus tandem repeats of a polyomavirus
enhancer; neo, neomycin resistance gene. (B) Photomicrographs of HtTA-1 cells 24 h after transfection of the indicated plasmid. Exposure times are not equivalent
for all photomicrographs.
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ment (17). As an additional control, PCR templates generated
from a primer containing the GFP start codon (primer 1) gave
no expression (Fig. 3A), supporting the premise that transcrip-
tional activation observed in this assay was due primarily to
upstream sequences in the TR. Since templates derived from
primer 4 included the putative D element initiator sequence,
two additional variants of primer 4 carrying severe mutations
of the canonical initiator sequence as previously described
were tested (25, 26). PCR products generated from these mu-
tations had no consistent effect on GFP expression, indicating
that the initiator sequence, as currently identified, is not re-
sponsible for TR transcript initiation observed in our assays.
Likewise, hybrid templates, generated using primer 8, which
carries the A element initiator-like sequence coupled to the
insufficient primer 3 sequence amplified from an A element-
deleted plasmid (TR-pneo/mp), did not increase GFP expres-
sion beyond that observed with primer 3 alone. This suggests
FIG. 2. (A) Diagram of the TR in genome form as packaged in the virion (top) and as cloned into a plasmid (bottom). The TR forms a T-shaped structure
containing one continuous strand in the virion. In the plasmid the TR is double stranded and contains the A, B, and C regions and their complements, A9, B9, and C9.
The location within the terminal repeat, intron, or GFP gene of 59 primers 1 to 7 are also shown. Primer 1 spans 213 to 16 of the GFP gene, primer 2 spans 23 to
115 of the SV40 intron (sequences 59 of the GFP gene and the intron are polylinker regions), primer 3 spans nt 139 to 145 of the TR plus 15 nt of the polylinker, primer
4 spans nt 110 to 127 of the TR, primer 5 spans nt 104 to 122, primer 6 spans nt 88 to 105, and primer 7 spans nt 60 to 77. (B) RT-PCR products were amplified using
primer 2 from RNA isolated from transfected 293 cells and analyzed by agarose gel electrophoresis. Lanes: 1 to 3, TR-pneo (Fig. 1)-transfected cells; 4 to 6,
TR/CMV/GFP-transfected cells; 7 to 9, mock-transfected cells that were spiked with TR-pneo DNA at cell harvest; 1, 4, and 7, untreated mRNA; 2, 5, and 8, RNA
samples treated with S1 nuclease prior to RT-PCR; 3, 6, and 9, RNA samples treated with NaOH to degrade RNA prior to RT-PCR. The 39 primer paired with primer
2 was located in the GFP gene: GFP-RT2 (nt 145 to 126 of the EGFP gene). Either GFP-RT2 or GFP-RT1 (nt 19 to 3 of the EGFP gene) was paired with the 59 primers
from panel A, as delineated in Table 1.
TABLE 1. Primers used in this study










Primer 2 GFP-RT2 1 1 Yes
Primer 3 GFP-RT2 1 1 Yes
Primer 4 GFP-RT1 1 1 NTc
Primer 5 GFP-RT1 1 1 NT
Primer 5 GFP-RT2 1 1 NT
Primer 6 GFP-RT1 1 1 NT
Primer 6 GFP-RT2 1 1 NT
Primer 7 GFP-RT1 2 2 NT
a A series of 59 primers were used with RT-PCR products from RNA isolated
from TR-pneo-transfected cells (Fig. 2). Primer sequences and locations are
described in the legend to Fig. 2.
b 1, product of the correct size detected; 2, no product of the correct size
detected.
c NT, not tested.
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that the putative A element initiator is not sufficient to initiate
transcription under these conditions.
We determined that sequences of the TR amplified by prim-
er 4 (nt 109 to 145) are sufficient to express GFP from a linear
DNA template in a transfection assay. To ensure that these
results were not related to the total length of the 59 sequences,
our PCR products generated with primer 8 (Fig. 3A) contained
the same amount of 59 DNA as did templates generated with
FIG. 3. (A) 59 PCR primers to the indicated regions were paired with a GFP poly(A) region primer to amplify products containing portions of the TR or intron
and the entire GFP gene. After transfection of the PCR products into HtTA-1 cells, relative positive cell counts and relative field fluorescence were determined from
a random field with a 103 objective (eight fields per well, two wells per condition). Cell counts were obtained for three independent experiments and are expressed
as a mean percentage of that obtained for primer 5 6 the standard error. Whole-field fluorescence, averaged from two of the same experiments, was corrected for cell
autofluorescence by subtracting the background of mock-transfected cells and are also expressed as a percentage of the intensity obtained with primer 5. Primer 4 M1
contains nt 110 to 138 of the TR, except that CCA at nt 128 to 130 was changed to GGG. Primer 4 M2 contains nt 110 to 138 of the TR, except that CT at nt 126 and
127 was changed to GA. Primer 8 consists of nt 72 to 93 linked to nt 139 to 145 of the TR plus 15 nt of polylinker (primer 3) and amplified from TR-pneo/mp.
TR-pneo/mp is derived from TR-pneo by digestion with MscI and PstI, blunting, and then religating the backbone with the GFP fragment. This plasmid contains only
nt 119 to 145 of the TR. p, two of three experiments with this primer showed no positive cells (in one experiment, two faint green cells of unknown origin were detected);
†, because whole-field measurements cannot distinguish between specific GFP fluorescence and cell autofluorescence due to cell death, these values contain more
variability than the cell count measurement. (B) Photomicrographs of 293 cells 48 h after transfection of the PCR products illustrated above each photograph. Exposure
times were equivalent. All PCR products were derived using the same 39 poly(A) signal primer. Plasmid and 59 primers were as follows: I, TR/CMV/GFP (Fig. 1) with
primer 4; II, TR-pneo (Fig. 1) with primer 2; III, TR-pneo with primer 4; IV, TR-pint (Fig. 1) with primer 4.
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primer 4. Even under these conditions, primer 8-derived tem-
plates did not yield efficient GFP expression. Although the TR
sequence appeared to contain a classic initiator sequence, as
determined by sequence homology of published initiator ele-
ments, results obtained with PCR templates generated from
specific mutant initiator primers strongly suggest otherwise.
Our study shows that the AAV-TR element has RNA initia-
tion capacity, maps to nt 109 to 145, and does not use a classic
initiator-like element to generate this activity. No other obvi-
ous sequence motif could be identified as a candidate for
mRNA initiation; therefore, further experiments are required
to determine the exact mechanism of mRNA initiation from
this region. While our experiments clearly demonstrate a role
for this sequence in the PCR-based transfection assay, we
extended these observations by testing for GFP expression by
generating a promoter-minus recombinant AAV and assaying
in vivo.
AAV-TR vector expression in vivo. It is clear from the ex-
periments above that in plasmid or PCR-derived linear DNA
form, the AAV terminal repeat can initiate the transcription
of a reporter gene (the PCR template gives 2.9% of the ex-
pression obtained with the CMV template). However, this
expression is only a concern if the TR promoter activity is also
present when delivered in a recombinant virus. Therefore,
virus AAV TR-pneo was generated from TR-pneo by the Uni-
versity of North Carolina vector core facility by standard meth-
ods (12). AAV TR-pneo was microinjected into two regions of
the brains of rats and analyzed as described by Haberman et al.
(13). GFP expression was seen 2 weeks later in both regions
injected: the hypothalamus and the inferior colliculus (Fig. 4).
These results demonstrate that the AAV TR can generate
reporter gene expression from a virus vector template as well
as in plasmid form. More importantly, in vivo expression indi-
cated that this promoter activity is not limited to tissue culture
cells and may influence gene expression from rAAV vectors in
the intact animal. Based on all our in vivo data established to
date, we typically observed from the TR-only vectors about 2 to
5% of the level of expression seen with a wild-type CMV
vector. This small amount of activity may arise as a result of
AAV DNA integration 39 of endogenous promoters. However,
GFP expression was similar in all cells in all animals, which
would not be expected if the expression was due to random
integration. Supporting this conclusion, AAV has been dem-
onstrated to last for long periods as episomes in muscle (5, 33).
More recently, AAV TR vectors coinfected with enhancer
sequences demonstrated significant expression from episomal
templates in vivo (6, 29).
Transcriptional activity within terminal repeat sequences of
viruses is not a novel discovery. This activity is essential for the
retrovirus life cycle (32) and has been detected in other DNA
viruses such as adenovirus (19, 24). Observation of transcrip-
tional activity from the AAV TR supports previous observa-
tions seen in rabbit and monkey lung (4, 20). The exact role
that this activity may play in wild-type AAV infection remains
unknown. In addition, it is not clear if the activity is restricted
to specific cell types or ubiquitous. We demonstrated, using
plasmid and PCR linear templates, that the primary sequences
necessary for activity in vitro are contained in the D element
and the 39 half of the A element. However, we did observe
transcripts (only from RT-PCR) which initiated 59 to the A/D
junction, suggesting that the GC-rich secondary structure of
the terminal repeat may also influence gene expression. In
addition, neither of the two putative consensus initiator se-
quences, as described in the literature, appear to be responsi-
ble for the observed activity. Since the TR contains all of the
essential functions required to generate AAV vectors (Rep/
RBE binding, trs resolution, origin of replication, and packag-
ing signals), we were not able to test the mini-TR expression
cassettes in the context of a virus. However, our in vivo studies
confirm that TR promoter activity is a very real phenomenon
FIG. 4. In vivo expression of TR-driven GFP. Virus made from a TR-pneo (AAV TR-pneo) was injected into the inferior colliculus and the hypothalamus of rats;
2 weeks later, the brains were sectioned and analyzed for GFP fluorescence by fluorescent microscopy. Many cells from each animal are visible in both regions of the
brain.
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that can occur in the intact animal. This observation may partly
explain some of the published observations for neurotropism
of AAV transduction in the brain (3). In addition, a loss of
tissue-specific expression, when in the context of the AAV
vector (N. Muzyczka, personal communication) may be related
to TR transcriptional activity and repression. The implications
of TR promoter activity on the use of AAV vectors will prob-
ably depend on the gene to be expressed, the promoter used,
and the location of virus transduction in vivo. Our studies
suggest that the most prominent impact of this activity will be
on the regulation of gene expression. Attempts to reduce ex-
pression completely in transduced cells through the use of reg-
ulated promoters or cell-type-specific promoters may be influ-
enced by TR promoter activity. Current vectors may have to be
modified before they can be used effectively in such instances.
Although we have not mapped the AAV TR transcriptional
activity to the nucleotide level, this region of the AAV TR has
been extensively characterized regarding its function in repli-
cation and packaging of the viral DNA. The A region contains
the AAV RBE and the trs, both of which are required for virus
replication. The Rep protein binds to the terminal repeat bind-
ing element and nicks the DNA downstream at the trs during
replication of the genome (28). The nucleotide requirements
for terminal resolution have recently been mapped to a region
that spans the A/D junction (2). One could try to mutate the
TR in an effort to abolish the promoter activity; in fact, single-
nucleotide mutations can be made without eliminating nicking
of the correct site, but small decreases in nicking efficiency
could have drastic effects on the ability to produce high-titer
recombinant virus. In addition, spacing mutations have been
generated, indicating that the correct distance from the RBE
to the trs is crucial for AAV replication (28, 36). Results ob-
tained with deletion mutations through the D sequence stress
the importance of this region in packaging (35; Xiao and Sam-
ulski, unpublished). Given these data, it is unlikely that elim-
ination of the TR promoter activity by traditional mutagene-
sis analysis will yield viable AAV vectors. Such mutations will
probably impair viral replication and/or packaging. Since the
sequences at the A/D junction are highly conserved between
AAV serotypes 1 to 4 and 6, with lower conservation for type
5 (2), TR transcriptional activity may exist for all serotypes.
Therefore, an underlying role for this activity may be essential
for the virus life cycle (e.g., initiating wild-type virus replication
or promoting templates suitable for integration). Regardless of
the function in wild-type virus, this is clearly an uncontrolled
activity that is part of the current AAV vectors.
It is of interest that the many strategies aimed at resolving
the small packaging constraint of AAV have not considered
the impact of TR promoter activity. Numerous studies are now
suggesting the use of AAV “split vectors” to overcome the size
limitation (6, 16, 29). The typical approach with these systems
depends on one vector carrying the 59 half of a specific gene
flanked by the promoter and splice donor and another vector
carrying the remaining 39 portion of the gene flanked by the
splice acceptor and a poly(A) signal. Expression of a functional
gene product occurs only after recombination or reannealing
through a common TR sequence from the appropriate two
split gene vectors. While this and other similar strategies ef-
fectively double the packaging size of AAV, our TR data
would indicate that such approaches may also increase the risk
of expressing truncated gene products from TR transcriptional
elements. This could lead to expression of aberrant proteins
that may have transdominant negative activity, elicit an im-
mune response, or interfere with pathways for normal secre-
tion of the therapeutic protein (e.g., factor IX). Since the
current AAV vectors are noted for safe, long-term expression
with a lack of immune response, these new vectors may have to
incorporate other components to eliminate the risk of un-
wanted expression from the TR.
Although the elimination of AAV TR promoter activity by
mutation is not likely to yield viable virus, the use of insulator
sequences adjacent to the TRs may provide an alternative.
Insulator sequences that block the transcriptional activation of
downstream promoters by enhancers have been tested in other
viral vectors (31). Although adding insulator sequences to an
already space-constrained vector may seem counterproductive,
the significant benefit of greater control of gene expression will
be necessary in some circumstances. Small insulator sequences
(approximately 200 bp) have been identified that may resolve
the size constraint in rAAV vectors (31). Alternatively, inser-
tion of a poly(A) signal between the TR and the cassette of
interest may blunt the unwanted expression via the TR. It
appears that a number of approaches can be tested to elimi-
nate residual transcriptional activity from the TR, and these
new TR expression minus vectors should have a significant
impact on the ability to utilize exogenous regulation systems
and cell-type-specific promoters within an AAV vector context.
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